MultiStem Administration for Stroke Treatment and Enhanced Recovery Study

Lead PI: N/A

Status: Site Selection

No. of Patients Currently Recruited: 0                               No. of Patients Required: 300 Globally

MASTERS-2 is a Phase III, double blind, randomised, placebo-controlled study designed to evaluate the efficacy of allogenic, regenerative therapy, MultiStem(R), on the functional outcome of patients with acute cortical ischaemic stroke. MultiStem is administered intravenously to patients within 36 hours of symptom onset.  

Trial URL: 

MASTERS-1 Phase II Trial:

24 June 2021

Related Posts